TY - JOUR
T1 - Pharmaceutical studies for gene therapy
T2 - Expression of human Cu,Zn - Superoxide dismutase gene transfected by lipofection in rat skin fibroblasts
AU - Nishiguchi, Kohshi
AU - Ishida, Kazue
AU - Nakajima, Masanori
AU - Maeda, Tetsuo
AU - Komada, Fusao
AU - Iwakawa, Seigo
AU - Tanigawara, Yusuke
AU - Okumura, Katsuhiko
PY - 1996/8
Y1 - 1996/8
N2 - To evaluate whether lipofection using Lipofectin(TM) is suitable for delivering foreign genes into skin fibroblasts as target cells, we performed experiments using human superoxide dismutase (hSOD) and neomycin-resistance (Neo1) genes as models in rat skin fibroblasts (FR and primary cells) in vitro. The amounts of DNA used in the lipofection procedure significantly affected the transfection efficiencies, and the optimal amounts were determined for all cells used. However, the efficiencies in rat skin fibroblasts were about 20-fold higher than that in rat lung epithelial-like cells (L2 cells). The differences in plasmid vectors (pRc/RSV-SOD and pRc/CMV-SOD) hardly affected the transfection efficiencies. The amounts of Lipofectin(TM) significantly affected the transfection efficiencies, and the optimal amounts were determined for both types of skin fibroblasts. However, cytoxic effects in both skin fibrobalsts were observed with high doses of Lipofectin(TM). On the other hand, with optimal amounts of DNA and Lipofectin(TM), the reporter gene (Neo1) introduced into cells was mainly integrated into the host cell chromosome. Western blot analysis showed the continuous expression of hSOD protein for at least 45 d in skin fibroblasts transfected with the expression plasmid for hSOD by Lipofectin(TM) under the optimal conditions, and the cellular SOD activity fluctuated in parallel with the expression of hSOD protein. Differences in the type of cells also affected the expression of hSOD. These results indicate that it is necessary to set up optimal conditions for transfection using Lipofection(TM) for each cell type, and that transfection with Lipofectin(TM) under optimal conditions may be an efficient method for introduction of foreign genes into skin fibroblasts for use as a clinical delivery system of therapeutic protein.
AB - To evaluate whether lipofection using Lipofectin(TM) is suitable for delivering foreign genes into skin fibroblasts as target cells, we performed experiments using human superoxide dismutase (hSOD) and neomycin-resistance (Neo1) genes as models in rat skin fibroblasts (FR and primary cells) in vitro. The amounts of DNA used in the lipofection procedure significantly affected the transfection efficiencies, and the optimal amounts were determined for all cells used. However, the efficiencies in rat skin fibroblasts were about 20-fold higher than that in rat lung epithelial-like cells (L2 cells). The differences in plasmid vectors (pRc/RSV-SOD and pRc/CMV-SOD) hardly affected the transfection efficiencies. The amounts of Lipofectin(TM) significantly affected the transfection efficiencies, and the optimal amounts were determined for both types of skin fibroblasts. However, cytoxic effects in both skin fibrobalsts were observed with high doses of Lipofectin(TM). On the other hand, with optimal amounts of DNA and Lipofectin(TM), the reporter gene (Neo1) introduced into cells was mainly integrated into the host cell chromosome. Western blot analysis showed the continuous expression of hSOD protein for at least 45 d in skin fibroblasts transfected with the expression plasmid for hSOD by Lipofectin(TM) under the optimal conditions, and the cellular SOD activity fluctuated in parallel with the expression of hSOD protein. Differences in the type of cells also affected the expression of hSOD. These results indicate that it is necessary to set up optimal conditions for transfection using Lipofection(TM) for each cell type, and that transfection with Lipofectin(TM) under optimal conditions may be an efficient method for introduction of foreign genes into skin fibroblasts for use as a clinical delivery system of therapeutic protein.
KW - Lipofectin(TM)
KW - gene therapy
KW - skin fibroblast
KW - superoxide dismutase
UR - http://www.scopus.com/inward/record.url?scp=0029779674&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029779674&partnerID=8YFLogxK
U2 - 10.1248/bpb.19.1073
DO - 10.1248/bpb.19.1073
M3 - Article
C2 - 8874819
AN - SCOPUS:0029779674
VL - 19
SP - 1073
EP - 1077
JO - Biological and Pharmaceutical Bulletin
JF - Biological and Pharmaceutical Bulletin
SN - 0918-6158
IS - 8
ER -